Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Glaucoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Glaucoma
    TopAbstracts in Glaucoma 09/22/2008 - (DGNews)
    TopAbstracts in Glaucoma 08/25/2008 - (DGNews)
    TopAbstracts in Glaucoma 07/28/2008 - (DGNews)
    Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk - (DGNews)
    TopAbstracts in Glaucoma 06/30/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Glaucoma
      Enhancing Adherence with Glaucoma Therapy: Practical Strategies for Superior Outcomes
      Glaucoma Progression: Detection and Management
      Managing Concomitant Eye Diseases: Expert Views on Glaucoma and Dry Eye
      Topics in Glaucoma Management: Systemic Effects of Medications
      Update on Glaucoma Treatment: ACT: Applying Trial Data on Fixed-Combination Therapy to Daily Clinical Practice

      Webcasts/CME archive

       Recent cases - Glaucoma
        Good Functional Recovery Following Intervention for Delayed Suprachoroidal Haemorrhage Post Bleb Needling: A Case Report
        Acute Bilateral Simultaneous Angle Closure Glaucoma After Topiramate Administration
        Topiramate-Induced Bilateral Angle-Closure Glaucoma
        Bilateral Acute Angle Closure Glaucoma as a Presentation of Isolated Microspherophakia in an Adult: Case Report
        Vascular Compression of the Optic Chiasm Resembling Glaucoma-Like Visual Field Defects

        Cases archive
          




        my personal edition > glaucoma > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Fixed-Dose Xalacom (latanoprost/timolol) Effective in Treating Glaucoma, and Patients Express Strong Preference for Single-Drop Regimen: Presented at ARVO

        By Earl R. Nichols

        FT. LAUDERDALE, FL -- May 9, 2005 -- Patients using latanoprost (Xalatan) and timolol (0.5%) in an unfixed combination to treat their glaucoma experience the same lowering of intraocular pressure when they switch to Xalacom, a single fixed-dose combination of the two drugs.

        In a study presented here at the Association for Research in Vision and Ophthalmology Annual Meeting, the reductions in intraocular pressure (IOP) seen with either treatment were similar. However, patients overwhelmingly preferred the fixed-dose agent.

        Megumi Iizuka, MD, resident in ophthalmology, University of Toronto, Toronto, Canada, presented the findings of a study on patients with chronic open angle glaucoma or ocular hypertension who were randomized to continue with their usual latanoprost plus timolol regimen (n=25) or receive the fixed-dose, single agent Xalacom (n=24).

        Intraocular pressure was measured at baseline and again at weeks 4 and 12. Mean age of patients was 67 years.

        Dr. Iizuka reported that there was no significant difference in the IOP reductions at weeks 4 and 12 for the two groups.

        Among patients using the two medications concomitantly, the IOP was 15.7 mm Hg at week 4, and 15.5 mm Hg at week 12. For those receiving the fixed dose, the IOP was 16.2 mm Hg at week 4, which was a "weakly significant" change from baseline, Dr. Iizuka said. At week 12, the IOP was 16.2 mm Hg, which was also not a significant difference.

        In no case did these changes represent a change of more than 1 mmHg from baseline (i.e., when they were already using latanoprost plus timolol), Dr. Iizuka said.

        Adverse events were similar between groups, with 6 patients reporting some ocular or systemic adverse events among the 24 who were using the two drugs separately, compared to 7 of the 23 who used the fixed dose combination.

        Although the differences in IOP reduction were not significant in this study, patients expressed a strong preference for the fixed dose combination. All but one said they preferred the single dose fixed combination, and this was reflected in the fact that they felt they were less likely to miss doses because the drug was administered as a single daily drop.

        Xalacom is approved for use only in the European Union and in Canada, Dr. Iizuka said.


        [Presentation title: Xalacom Fixed Combination versus Timoptic XE and Xalatan Unfixed Combination: A Study of Effectiveness and Safety in the Treatment of Open Angle Glaucoma and Ocular Hypertension. Poster 2460/B13]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send